Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

DRAK2 Antikörper (C-Term)

STK17B Reaktivität: Human WB, IF, EIA Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN499770
  • Target Alle DRAK2 (STK17B) Antikörper anzeigen
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Bindungsspezifität
    • 10
    • 7
    • 6
    • 6
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reaktivität
    • 41
    • 16
    • 8
    • 1
    • 1
    • 1
    Human
    Wirt
    • 38
    • 2
    • 1
    Kaninchen
    Klonalität
    • 40
    • 1
    Polyklonal
    Konjugat
    • 20
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser DRAK2 Antikörper ist unkonjugiert
    Applikation
    • 29
    • 25
    • 8
    • 3
    • 3
    • 3
    • 1
    Western Blotting (WB), Immunofluorescence (IF), Enzyme Immunoassay (EIA)
    Spezifität
    DRAK2 antibody was raised against a peptide corresponding to amino acids 351 to 365 of human DRAK2. It has no cross responses to DAP or ZIP kinases.
    Aufreinigung
    Ion exchange chromatography
    Immunogen
    Human DRAK2 (C-Terminus) Peptide
    Isotyp
    IgG
    Top Product
    Discover our top product STK17B Primärantikörper
  • Applikationshinweise
    ELISA. Western Blot: 1/500 to 1/1000. An approximately 45 kDa band can be detected. Theapproximately 70 kDa band is probably non-related to DRAK2 although it is peptideblockable. Immunocytochemistry.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Buffer
    PBS containing 0.02 % sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C
    Informationen zur Lagerung
    Store the antibody undiluted at 2-8 °C.
  • Target
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Andere Bezeichnung
    STK17B / DRAK2 (STK17B Produkte)
    Synonyme
    zgc:65989 antikoerper, STK17B antikoerper, DRAK2 antikoerper, Drak2 antikoerper, 3110009A03Rik antikoerper, AI120141 antikoerper, serine/threonine kinase 17b (apoptosis-inducing) antikoerper, serine/threonine kinase 17b antikoerper, stk17b antikoerper, STK17B antikoerper, Stk17b antikoerper
    Hintergrund
    Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues (1).Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2, Serine/threonine-protein kinase 17B
    Gen-ID
    9262
    UniProt
    O94768
Sie sind hier:
Kundenservice